Prion disease risk uncertainties associated with urine-derived and recombinant fertility drugs
| Autor: | Michael G. Tyshenko, Daniel Krewski, Michelle Wong, Neil R. Cashman, Ricky Cheung, Willy Aspinall |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Drug
medicine.drug_class media_common.quotation_subject prion disease Fertility Urine Disease Management Science and Operations Research Lower risk Bioinformatics medicine Business and International Management recombinant media_common Fertility drugs fertility Transmission (medicine) business.industry transmission Expert elicitation variant Creutzfeldt-Jakob disease uncertainties urine expert elicitation Statistics Probability and Uncertainty business |
| Zdroj: | Cashman, N R, Tyshenko, M G, Cheung, R, Aspinall, W, Wong, M & Krewski, D 2019, ' Prion disease risk uncertainties associated with urine-derived and recombinant fertility drugs ', International Journal of Risk Assessment and Management, vol. 22, no. 2, pp. 109-127 . https://doi.org/10.1504/IJRAM.2019.101292 |
| DOI: | 10.1504/IJRAM.2019.101292 |
| Popis: | The detection of prion protein in widely used urine-derived fertility drugs has raised the possibility that prions from urine donors with (asymptomatic) prion disease could be present in these drugs. A high level of uncertainty exists regarding this issue. An international expert panel provided judgments related to prion disease transmission through fertility drug use in a structured expert elicitation. The elicitation gauged expert judgements about the uncertainty surrounding potential prion disease risks associated with urine-derived fertility drugs and emphasised the scientific ambiguity surrounding disease transmission risk factors associated with urine-derived fertility drugs. Group aggregated responses indicate that the theoretical risk of prion disease transmission with urine-derived fertility drugs was judged to be very low. The experts judged recombinant fertility drugs produced with bovine serum to possess 10-fold lower risk compared to urine-derived fertility drugs. Fertility drugs made without fetal bovine serum were judged to present a risk approximately 1,200 times lower compared to urine-derived counterparts. This elicitation indicates recombinant fertility drugs carry relatively less risk than urine-derived fertility drugs. However, the associated uncertainties are significant and pro-active surveillance of possible new routes of transmission of human prion disease warrants consideration of new scientific data as it becomes available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|